U.S. retail sales rose more than expected in September, rounding out a strong quarter of economic activity, but the recovery from the recession is at a crossroads as government money runs out and new COVID-19 infections surge across the country.
U.S. factory production unexpectedly fell in September, suggesting that manufacturing's recovery from the COVID-19 pandemic was slowing heading into the fourth quarter.
A sudden tightening of social restrictions to tackle the resurgent coronavirus pandemic across Europe threatens to spoil any stock market boost third quarter earnings might bring.
The Philippines has lifted a moratorium on oil and gas exploration in the disputed South China Sea, which the government said Friday could fast-track talks with Beijing on a joint energy project.
LONDON: A bitter High Court clash between Barclays and British businesswoman Amanda Staveley, over whether she was deceived while negotiating a financial lifeline for the bank at the height of the credit crisis, draws to a close on Friday. Staveley is claiming hundreds of millions of pounds in ......
SINGAPORE: The Manpower Ministry (MOM) has suspended the work pass privileges of two employers after they failed to arrange for their workers to undergo mandatory rostered routine testing for COVID-19. Action was taken after the employers did not provide valid reasons or submit an exemption ...
Shares of gun makers have been gaining ground as Democratic candidate Joe Biden leads polls, and if he wins the presidential election in November there are expectations of a renewed surge in gun sales that could drive shares even higher.
BP is set to make around 7,500 compulsory redundancies after roughly 2,500 staff - or just over one in ten of those eligible - applied for voluntary severance, according to an internal memo seen by Reuters and company sources.
As Wall Street banks reported quarterly results this week, investors wondered about the staying power of the trading bonanza that has floated profits, offsetting problems in traditional lending businesses that have been hurt by the pandemic.
Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces complex insurance reimbursement ...
